dc.contributor.author
Llovet i Bayer, Josep Maria
dc.contributor.author
Johnson, Philip J.
dc.date.issued
2018-04-03T15:28:46Z
dc.date.issued
2018-04-03T15:28:46Z
dc.date.issued
2014-03-20
dc.date.issued
2018-04-03T15:28:46Z
dc.identifier
https://hdl.handle.net/2445/121235
dc.format
application/pdf
dc.publisher
American Society of Clinical Oncology
dc.relation
Reproducció del document publicat a: https://doi.org/10.1200/JCO.2013.54.3033
dc.relation
Journal of Clinical Oncology, 2014, vol. 32, num. 9, p. 968-969
dc.relation
https://doi.org/10.1200/JCO.2013.54.3033
dc.rights
(c) American Society of Clinical Oncology, 2014
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Medicina)
dc.subject
Assaigs clínics de medicaments
dc.subject
Càncer de fetge
dc.title
Reply to X. Qi et al ' Brivanib for Hepatocellular Carcinoma Trials: Selection Bias From Barcelona Clinic Liver Cancer Stage?'
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
